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Traumatic brain injury (TBI) survivors frequently suffer from life-long deficits in cognitive
functions and a reduced quality of life. Axonal injury, observed in many severeTBI patients,
results in accumulation of amyloid precursor protein (APP). Post-injury enzymatic cleavage
of APP can generate amyloid-β (Aβ) peptides, a hallmark finding in Alzheimer’s disease
(AD). At autopsy, brains of AD and a subset of TBI victims display some similarities includ-
ing accumulation of Aβ peptides and neurofibrillary tangles of hyperphosphorylated tau
proteins. Most epidemiological evidence suggests a link between TBI and AD, implying
thatTBI has neurodegenerative sequelae. Aβ peptides and tau may be used as biomarkers
in interstitial fluid (ISF) using cerebral microdialysis and/or cerebrospinal fluid (CSF) follow-
ing clinical TBI. In the present review, the available clinical and experimental literature on
Aβ peptides and tau as potential biomarkers following TBI is comprehensively analyzed.
Elevated CSF and ISF tau protein levels have been observed following severeTBI and sug-
gested to correlate with clinical outcome. Although Aβ peptides are produced by normal
neuronal metabolism, high levels of long and/or fibrillary Aβ peptides may be neurotoxic.
Increased CSF and/or ISF Aβ levels post-injury may be related to neuronal activity and/or
the presence of axonal injury.The heterogeneity of animal models, clinical cohorts, analyt-
ical techniques, and the complexity of TBI in the available studies make the clinical value
of tau and Aβ as biomarkers uncertain at present. Additionally, the link between early post-
injury changes in tau and Aβ peptides and the future risk of developing AD remains unclear.
Future studies using methods such as rapid biomarker sampling combined with enhanced
analytical techniques and/or novel pharmacological tools could provide additional informa-
tion on the importance of Aβ peptides and tau protein in both the acute pathophysiology
and long-term consequences of TBI.
Keywords: traumatic brain injury, biomarkers, Alzheimer’s disease, amyloid beta, tau, cerebrospinal fluid, micro-
dialysis
INTRODUCTION
In the United States, around 1.4 million people sustain a traumatic
brain injury (TBI) annually (Zohar et al., 2011; Sivanandam and
Thakur, 2012) and younger individuals are predominately affected
(Fins, 2003; Kovesdi et al., 2010). Depending on the severity of the
injury, survivors can experience significant impairments in cog-
nition and display marked personality changes, which can have a
negative impact both on the patient and the society (Magnoni
and Brody, 2010; Sivanandam and Thakur, 2012). The patho-
physiology of TBI is complex and involves multiple cellular and
biochemical changes generated by the initial impact, leading to a
disease process which exacerbate the injury for a prolonged period
of time. This secondary injury process involves inflammatory
cascades and heterogenous cell death pathways including apop-
tosis, autophagia, and necrosis (Kovesdi et al., 2007; Loane et al.,
2009; Marklund and Hillered, 2011; Sivanandam and Thakur,
2012). Due to individual patient factors and initial injury char-
acteristics, TBI produces either a focal lesion (cortical contusions,
epi-subdural, or intracerebral hemorrhages), diffuse injury (dif-
fuse axonal injury, DAI, and/or diffuse brain swelling; Strich, 1956;
Yarnell and Ommaya, 1969; Gennarelli et al., 1982; Adams et al.,
1989; Povlishock et al., 1992), or a mixture thereof (Saatman et al.,
2008). There are substantial differences among these injury types
and clinical TBI characteristics are markedly heterogeneous.
Importantly, wide-spread injury to white matter tract axons
has emerged as a crucial contributor to the morbidity observed
in TBI survivors (Smith and Meaney, 2000; Smith et al., 2003c;
Czeiter et al., 2008). In injured axons, amyloid precursor pro-
tein (APP) accumulates mainly due to a TBI-induced disruption
of axonal transport (Pierce et al., 1996). In addition, increased
neuronal APP expression has also been observed in human and
animal models and across the spectrum of severe TBI (Otsuka
et al., 1991; Sola et al., 1993; Lewen et al., 1995; Pierce et al., 1996;
Murakami et al., 1998; Ciallella et al., 2002; Itoh et al., 2009). Thus,
elevated APP levels in injured axons may be due to a combina-
tion of increased neuronal expression and accumulation due to
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disrupted axonal transport. When APP is proteolytically cleaved
by β- and γ-secretases, amyloid-β (Aβ) peptides of various lengths
can be produced by normal cell metabolism and be released from
the presynaptic ending of the axon in the uninjured brain (Price
et al., 1995; Blennow et al., 2006; Masters et al., 2006). Experimental
TBI results in increased gene and protein expression of β-secretase
1 (BACE1; also named β-site APP cleaving enzyme 1), the major
β-secretase involved in the production of Aβ from APP in neu-
rons (Cai et al., 2001; Blasko et al., 2004; Loane et al., 2009; Yu
et al., 2012a). Although the γ-secretase presenilin-1 and BACE1
were not co-transported with APP in the sciatic nerve (Lazarov
et al., 2005), BACE1 protein was found to co-accumulate with
APP in injured axons following TBI in the pig (Chen et al., 2004)
and in patients dying within weeks post-injury (Uryu et al., 2007).
Additionally, presenilin-1 may also co-accumulate with APP in
injured axons (Uryu et al., 2007). As will be discussed in the sub-
sequent paragraphs, an association between APP accumulation
and Aβ formation in injured axons, post-injury plaque deposition
and the development of Alzheimer’s disease (AD) has not been
firmly established. However, Aβ was found to co-accumulate with
APP in injured axons up to 6 months post-injury in a miniature
swine TBI model and at autopsy up to 3 years following human
TBI (Chen et al., 2004, 2009). Combined, these reports argue that
TBI may result in an increased production of Aβ peptides from
APP. Since increased Aβ peptide generation may have neurotoxic
properties and aggregate into plaques and oligomers (vide infra), it
may have important implications in the secondary injury cascade
post-TBI.
Alzheimer’s disease, the most common neurodegenerative dis-
ease, affects more than 25 million people worldwide and shows
a rapidly increasing prevalence (Blennow et al., 2006). AD is pri-
marily characterized by progressive cognitive impairments includ-
ing loss of episodic memory and language, impaired judgment,
decision-making, and orientation. Neuropathology is diagnostic
and extracellular plaques of Aβ peptides and neurofibrillary tan-
gles (NFTs) composed of hyperphosphorylated tau proteins are
typically found in the brains of AD patients (Blennow et al., 2006;
Trojanowski et al., 2010; Kennedy et al., 2012; Weiner et al., 2012).
More than two decades ago, it was postulated that a single, severe
TBI may result in dementia with early onset (Clinton et al., 1991).
Specifically, TBI was suggested to be an independent risk factor for
AD in many studies (Clinton et al., 1991; Gualtieri and Cox, 1991;
Mortimer et al., 1991; Breteler et al., 1992; Mayeux et al., 1993;
Guo et al., 2000). A re-analysis of 11 case control studies (Mor-
timer et al., 1991) and results from a cohort of 548 injured WWII
veterans (Plassman et al., 2000) found that the risk for developing
AD following TBI can be increased up to 4.5-fold. The associ-
ation between AD and TBI was further strengthened by clinical
and experimental studies demonstrating that in brain tissue from
TBI survivors or from brain-injured animals, pathological find-
ings with a resemblance to those of AD were observed (Guo et al.,
2000; Johnson et al., 2010; Magnoni and Brody, 2010). A genetic
factor for AD, the ε4 allele of the lipid transport apolipoprotein
E (Apoε4) seems to worsen the prognosis following TBI and pre-
dispose to the formation of Aβ plaques in AD (Nicoll et al., 1995;
Kim et al., 2009). These reports argue that TBI may be a risk fac-
tor for the long-term development of AD (Mortimer et al., 1991;
Plassman et al., 2000; Fleminger et al., 2003; Johnson et al., 2010;
Magnoni and Brody, 2010).
Despite this suggested link between TBI and AD, numerous
unanswered questions remain. For instance, is the increased risk of
AD after TBI a direct consequence of cascades initiated at the time
of impact, reflected by initial changes in Aβ and tau levels in brain,
cerebrospinal fluid (CSF), and/or interstitial fluid (ISF)? Alter-
natively, does the TBI-AD link merely reflect a hastened cognitive
decline and/or a reduced cognitive reserve induced by TBI? Specif-
ically, in recent in vivo studies, Aβ and/or tau have been analyzed
as biomarkers in both the experimental and clinical TBI setting
in the CSF or in the ISF using microdialysis (MD). Although the
analysis of phospho-tau and Aβ peptides is crucial in the diagno-
sis of AD (Mattsson et al., 2012), the interpretation of tau and Aβ
peptides following TBI is unclear. Compared to most AD models,
the data on Aβ and tau formation following experimental TBI are,
to some extent, highly heterogeneous and AD pathology has not
been robustly confirmed. In fact, rodent TBI models have been
unable to show the hallmark findings of NFTs and Aβ plaques
post-TBI. Regardless, since tau and Aβ levels may markedly influ-
ence the pathophysiology of TBI, both acutely and at long-term,
they can potentially be used as biomarkers. In this review, we focus
on the available evidence for increased Aβ and tau pathology in
injured brain tissue and the use of Aβ peptides and tau as potential
biomarkers in the CSF and ISF following TBI.
Aβ AND TAU HISTOPATHOLOGY FOLLOWING TBI-ANIMAL
STUDIES
Due to the heterogeneity of clinical TBI, numerous animal models
exist (Marklund and Hillered, 2011). To date, most TBI stud-
ies evaluating tau and Aβ have used the focal controlled cortical
impact (CCI) model, and only infrequently have models of diffuse
TBI producing wide-spread axonal injury been evaluated (Tables 1
and 2). In initial TBI studies in rats, immunohistochemical analy-
sis (IHC) revealed accumulation of APP in injured axons although
Aβ peptides were not detected (Lewen et al., 1995; Pierce et al.,
1996). Instead, mice overexpressing human APP [APP-yeast artifi-
cial chromosome (APP-YAC mice), PDAPP, and recently 3xTg-AD
mice] displaying Aβ plaque pathology were developed and studied
using the CCI model (Murai et al., 1998; Nakagawa et al., 1999,
2000; Hartman et al., 2002; Uryu et al., 2002; Conte et al., 2004;
Tran et al., 2011a, 2012) (Table 1). Non-transgenic mice“knocked-
in” with the human Aβ coding sequence to their endogenous APP
gene (APPNLh/NLh) have also been developed (Abrahamson et al.,
2006, 2009). Although these models failed to mimic the formation
of Aβ plaques similar to that observed in humans, findings such
as exacerbated cell death and brain atrophy in APP-overexpressing
mice were noted post-TBI (Smith et al., 1998). Since a decreased
plaque load was found in aged plaque-forming PDAPP transgenic
mice following TBI, plaque pathology may be potentially reversible
(Nakagawa et al., 2000).
When rats were evaluated in the impact/acceleration and lat-
eral fluid percussion injury models, both showing wide-spread
axonal injury, long-term accumulation of Aβ in injured axons
was noted although not Aβ plaques (Iwata et al., 2002; Stone
et al., 2002; Tian et al., 2012). Although recent studies using
various Enzyme-Linked Immunosorbent Assay (ELISA) and
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Table 2 | Animal studies on traumatic brain injury (TBI) and tau.
Reference Animal Age Animal
model
Tau detection
technique
Tau
type
Time
detected
Major findings
Hoshino
et al. (1998)
Rat 3 m LFP IHC P-tau 6 m Six months after TBI, numerous neurons were
immunoreactive for P-tau or Aβ
Smith et al.
(1999)
Pig 4 m RA IHC T-tau 3–10 d Accumulations of T-tau and NF-rich inclusions were
found in neuronal perikarya. Tau accumulated in most
axonal bulbs
Liliang et al.
(2010a)
Rat N/A WD ELISA, WB T-tau 1–6 h T-Tau levels ↑↑ at 1 h, returned to baseline by 6 h
post-injury. Tau levels were higher in the severe TBI
group compared to the mild TBI group
Genis et al.
(2000)
ApoE-deficient
mice
4 m WD CHI WB P-tau,
T-tau
4–24 h P-tau increased at baseline in transgenics. In WT
controls, P-tau ↑ at 4 h post-TBI, returned to baseline
at 24 h. Minimal increase in P-tau in transgenics,
clearly less than in WT controls
Yoshiyama
et al. (2005)
T44tauTg and
WT non-Tg
mice
12 m Mild
repetitive
BC, IHC, WB NFT* 9 m Behavioral outcome not impaired 6 months post-TBI.
Only one Tg T44 mouse only showed extensive NFTs
and cerebral atrophy
Gabbita
et al. (2005)
Adult rat1 Adult CCI ELISA, IB C-tau 6–168 h C-tau levels was increased at 6 h post-TBI, peaked at
168 h post-injury. Elevated brain C-tau levels
associated with TBI-induced tissue loss
Tran et al.
(2011a)
3xTg-AD and
wild-type
B6/SJL mice
5–7 m CCI ELISA, IHC,
WB
P-tau 24 h–7 d In 3xTg-AD mice, TBI resulted in increased
intra-axonal phospho-tau immunoreactivity after TBI
Tran et al.
(2011b)
3xTg-AD,
APP/PS1,
TauP301L mice
2–6 m CCI IHC, WB T-tau,
P-tau
1–24 h Increased tau pathology early in 3xTg-AD and
TauP301L mice with a peak at 1 and 24 h post-TBI.
Increase in contralateral hippocampus beginning at
12 h post-TBI. P-tau increased in fimbriae and fornix
Tran et al.
(2012)
3xTg-AD mice 5–7 m CCI WB, IHC, HP P-tau 24 h Abnormal co-accumulation of several phosphorylating
kinases with tau at 24 h post-TBI. A JNK inhibitor
reduced P-tau accumulation in axons
Yu et al.
(2012b)
WT mice 7 w CCI IHC, WB,
ELISA
P-tau 3 d P-Tau was increased in the thalamus post-TBI; lithium
administration reduced P-tau at 3 d post-TBI, resulting
in improved spatial learning
Ojo et al.
(2013)
h-Tau mice 18 m Repetitive
mTBI
IHC P-tau 21 d Increased P-tau by repetitive, 48 h apart, mTBI
although not a single mTBI
In both focal and diffuse TBI models did the levels and expression of tau consistently increase post-injury.
APP, amyloid precursor protein; BC, biochemical analysis; CCI, controlled cortical impact; C-tau, cleaved-tau; ELISA, enzyme-linked immunosorbent assay; HP,
histopathological analysis; h-tau, mice overexpressing human tau; IB, immunoblotting; IHC, immunohistochemistry; LFP, lateral fluid percussion; m, month; P-tau,
phosphorylated tau; PS1, presenilin-1; JNK, c-Jun N-terminal kinase; RA, rotational acceleration; T-tau, total tau; N/A, data not available; NFT, neurofibrillary tangles;
TBI, traumatic brain injury; w, week; WB, western blotting; WT, wild-type; CHI, closed head injury; WD, weight drop; mTBI, mild traumatic brain injury; 1Age not
mentioned; *NFTs were observed in one mouse only suggesting this study was negative for producing a tauopathy post-injury.
immunohistochemical detection methods have shown increased
Aβ load in wild-type animals (Loane et al., 2009; Mannix et al.,
2011; Tian et al., 2012), the vast majority of rodent TBI mice mod-
els failed to replicate the Aβ plaque formation observed in humans
(see Table 1). To date, only in PDAPP-human APOε4 transgenic
mice was TBI found to accelerate Aβ plaque formation (Hartman
et al., 2002). Since the rodent Aβ sequence differs from the one
in humans at amino acid positions 5, 10, and 13 (Selkoe, 1989),
poor immunohistochemical detection techniques and less aggre-
gating properties of mouse Aβ was suggested (Smith et al., 1998).
At present, improved immunohistochemical methods have alle-
viated this problem of Aβ detection in rodents and additionally,
APP transgenic animals carry the human sequence. The increased
Aβ load noted in some animal TBI models may be dependent on
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the evaluated Aβ species, time span post-injury, and age of the
animal. It is also plausible that Aβ formation is more extensive in
TBI models with a higher degree of axonal injury.
Although rodent TBI models produce pathology similar to that
observed in humans, there are obvious differences in anatomy as
well as gray-white matter ratio, and rodents are also lissencephalic
(Morales et al., 2005; Marklund and Hillered, 2011). Thus, high-
order species may have advantages in terms of clinical relevance
and AD-like pathology was evaluated in a rotational acceleration
DAI model in miniature swine (Meaney et al., 1995; Smith et al.,
1997; Johnson et al., 2010). Although a smaller number of Aβ
plaques compared to TBI patients was observed, this model pro-
duced Aβ accumulation in injured axons in addition to plaque
formation (Smith et al., 1999; Chen et al., 2004). Furthermore,
diffuse Aβ plaques in both gray and white matter were identified
(Smith et al., 1999) and APP co-accumulated with Aβ post-injury
(Chen et al., 2004) (Table 1). This swine model appears suitable for
the study of Aβ pathology following TBI, particularly in relation
to axonal injury.
The microtubule-associated protein tau has six isoforms in
humans and is a normal constituent primarily of axons. In patho-
logical conditions such as TBI, tau can be hyperphosphorylated
(P-tau) and aggregate which is needed for the formation of NFTs
(Geddes et al., 1999; McKee et al., 2009; Ojo et al., 2013). Tau
dissociated from microtubuli can disperse not only by interneu-
ronal transfer but also via glial to glial spread (Genis et al.,
2000; Tran et al., 2011a,b), be involved in Aβ-induced neuro-
toxicity (Rapoport et al., 2002) and also be neurotoxic by itself
(Farias et al., 2011). The formation of NFTs has been observed
both following repetitive mild human TBI and many years fol-
lowing a single severe TBI in a subset of patients in addition
to its crucial role in AD. Tau formation has been evaluated in
numerous experimental TBI studies using Western Blot, ELISAs,
and immunohistochemistry (Hoshino et al., 1998; Smith et al.,
1999; Genis et al., 2000; Ikonomovic et al., 2004; Gabbita et al.,
2005; Yoshiyama et al., 2005; Uryu et al., 2007; Liliang et al.,
2010a,b; Tran et al., 2011a,b, 2012; Rostami et al., 2012; Yu
et al., 2012b; Ojo et al., 2013). The vast majority of rodent stud-
ies have used focal TBI models and evaluated changes in total
tau (T-tau), cleaved-tau (C-tau), and/or P-tau within the first
post-injury weeks (Table 2). Importantly, these rodent models
have not been able to reproduce the NFT pathology observed
in AD.
Several studies have used transgenic mice in the study of tau
pathology following TBI (Genis et al., 2000; Yoshiyama et al., 2005;
Tran et al., 2011a,b, 2012; Yu et al., 2012b). Although both wild-
type and Apoε-deficient mice showed tau hyperphosphorylation
post-injury following closed head injury, it was more marked in
wild-type controls (Genis et al., 2000). These important findings
need to be reproduced also in other TBI models. Importantly,accu-
mulation of phosphorylated tau over time may influence neuronal
structure and synaptic properties (Dickstein et al., 2010). Due to
the increasing interest in the long-term sequelae of mild repetitive
TBI in humans (e.g., concussions in sports), repeated mild TBIs
in mice have been evaluated. Although NFTs or behavioral deficits
were not induced by repeated mTBI in transgenic mice expressing
the shortest human tau isoform (Yoshiyama et al., 2005), increased
P-tau without NFT formation was observed following repeated
mTBI in aged mice overexpressing human tau (Ojo et al., 2013).
In summary, the swine, wild-type rodents, and transgenic mice
TBI models thus consistently showed increased tau protein levels
post-injury without producing the NFTs observed in AD. Impor-
tantly, most animal TBI studies negative for NFT formation have
only used short-term survival whereas NFT was only observed in
patients surviving for many years following severe TBI although
not in patients dying within 4 weeks of the injury (Smith et al.,
2003a; Johnson et al., 2012).
Aβ AND TAU HISTOPATHOLOGY FOLLOWING TBI-HUMAN
STUDIES
In approximately 30% of patients dying early from TBI,Aβplaques
was identified at autopsy across all age groups (Gentleman et al.,
1993, 1997; Roberts et al., 1994; Horsburgh et al., 2000; Smith et al.,
2003b; Uryu et al., 2007; Chen et al., 2009). Diffuse Aβ plaques
have been also observed by immunohistochemistry in surgically
removed focal injuries within days post-injury (Ikonomovic et al.,
2004; DeKosky et al., 2007). Aβ plaques have also been found in
injured axons of DAI patients dying <9 days post-injury (Smith
et al., 2003c). Importantly, wide-spread Aβ pathology can remain
for many years in the brains of survivors of moderate to severe
TBI (Johnson et al., 2010, 2012). Contrary to the diffuse plaques
observed acutely, these long-term Aβ plaques were more often fib-
rillary (Johnson et al., 2012). Since Aβ plaques are found in only
∼30% of TBI patients, the development of neurodegeneration
and/or AD likely has a multifactorial basis including altered expres-
sion of, e.g., the Aβ-degrading enzyme neprilysin gene which is
related with some forms of AD (Helisalmi et al., 2004). Notably,
neprilysin gene polymorphism was linked to the occurrence of Aβ
plaques following TBI (Johnson et al., 2009), raising the possibility
to screen individuals with a high risk of TBI such as participants
in contact sports or soldiers.
Numerous clinical reports have reported tau pathology, in par-
ticular an accumulation of NFTs, in the brains of athletes who
sustained several concussions during their career. This entity has
been named chronic traumatic encephalopathy (CTE) (Corsellis
et al., 1973; Roberts et al., 1990; Dale et al., 1991; Geddes et al.,
1999; McKee et al., 2009, 2013). Although these findings have
also been observed in athletes from a variety of different sports
including American football or ice hockey, they have been clas-
sically seen in the brains of up to 17% of former professional
boxers (previously named dementia pugilistica or “punch-drunk”
syndrome) (Roberts et al., 1990). Common symptoms in CTE
include memory loss, Parkinson-like movements, and dementia
(Roberts et al., 1990; Jordan et al., 1995; McKenzie et al., 1996;
McKee et al., 2009; Nowak et al., 2009). In CTE, the vast major-
ity of cases display wide-spread NFTs and Aβ pathology is much
less frequently observed (McKee et al., 2013). Recently, the largest
cohort of individuals to date with a history of repeated concus-
sions was analyzed where wide-spread tauopathy was observed
(McKee et al., 2013). Although these reports and others suggest
that repeated concussions/mTBI should be regarded very seriously,
the number of examined individuals is still low and the incidence
of CTE, its risk factors, and the contribution of other co-variables
has yet to be defined.
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Tau pathology, including high density and wide-spread NFTs,
was also observed in patients who suffered a single, severe TBI
1–47 years previously (Johnson et al., 2012). In this study, 39
patients with a single, severe TBI surviving for more than 1 year
post-injury were compared to 47 age-matched controls. Mean
survival was 8 years and NFTs were present in 34% of patients
<60 years old compared to 9% of controls of similar age. Addi-
tionally, the NFTs in TBI patients were commonly observed in
superficial cortical layers, in depths of the sulci, and clusters were
observed in the cingulate gyrus, the insular cortex, and the supe-
rior frontal gyrus. In contrast, NFTs were rarely observed outside
the transentorhinal cortex and the CA1 in controls (Johnson et al.,
2012). This study was the first to observe NFT at long-term fol-
lowing a single, severe TBI in humans although additional studies
including a larger number of patients are required for confirma-
tion of these findings. The long delay between the injury and
the NFT analysis and the large age span in this patient cohort
add to the inherent variability and many potential co-variables
may have contributed to the formation of NFTs (Johnson et al.,
2012). The process of delayed NFT formation in human TBI,
if at all present, remains to be defined. Early following severe
TBI, total and phospho-tau protein was found to accumulate
in both neuronal cell bodies and axons post-TBI in a subset
of patients (Smith et al., 2003a; Uryu et al., 2007) although
without clear NFT pathology. In surgically resected brain tis-
sue early post-injury, diffuse neuronal tau immunostaining was
observed in most patients, although only 2/18 patients showed
NFTs (Ikonomovic et al., 2004). In addition, NFTs were not found
in TBI patients who died within 4 weeks from injury (Smith
et al., 2003a), suggesting that the mechanisms leading to NFT
and/or CTE pathology requires a prolonged time post-injury to
develop.
Thus, numerous animal and human observations support a
link between AD and TBI. However, there are substantial clinical
and histopathological differences between AD and TBI (Johnson
et al., 2010). In the brains of CTE victims, P-tau immunoreactive
NFTs are found superficially in wide-spread cortical regions (Hof
et al., 1992; McKee et al., 2009) in contrast to AD where NFT are
predominately observed in deep cortical layers. Additionally, typ-
ical neuritic plaques with a dense core of fibrillar Aβ represent
a typical finding in AD patients, whereas diffuse Aβ plaques with
non-fibrillary Aβ are observed early in TBI (Horsburgh et al., 2000;
Johnson et al., 2010). The Aβ plaques observed in AD develop over
several years and are typically seen in older individuals in con-
trast to TBI, where Aβ plaques have been demonstrated as early
as 2 h post-injury and in young patients as well (Roberts et al.,
1994; Ikonomovic et al., 2004; Johnson et al., 2010). Addition-
ally, TBI Aβ plaques appear more in the gray matter in contrast
to AD (Smith et al., 2003b) and it is unclear whether the diffuse
TBI-induced Aβ plaques progress into the more solid and dense
plaques characteristic of advanced AD (Horsburgh et al., 2000;
Chen et al., 2009; Johnson et al., 2010, 2012). Several years follow-
ing a single, severe TBI, fibrillary Aβ plaques have been observed,
implying that TBI may accelerate the pathophysiological process
leading to AD. These data suggest that the mechanisms leading to
an increased risk for neurodegeneration and AD following TBI are
highly complex.
RATIONALE OF Aβ PEPTIDES AS BIOMARKERS
FOLLOWING TBI
In vitro and animal AD models indicate that Aβ accumulation, in
particular the soluble oligomeric form, may be a crucial initiating
factor in AD (LaFerla et al., 2007; Gouras et al., 2010) preced-
ing tau-related neurotoxicity (Hardy and Selkoe, 2002). However,
both in vitro and in vivo animal studies demonstrate that extra-
cellular Aβ concentrations are regulated by neuronal metabolism
and synaptic activity (Cirrito et al., 2005, 2008). The majority
(80–90%) of generated Aβ peptides consist of the 40-amino acid
long peptide Aβ1-40 (Aβ40). The longer Aβ1-42 (Aβ42) prote-
olytic variant is more hydrophobic and tends to aggregate into
plaques (Brody et al., 2008). In the experimental setting, Aβ may
be synaptotoxic (Claeysen et al., 2012; Koffie et al., 2012), neu-
rotoxic (Walsh et al., 2002), disrupt cellular membranes (Berman
et al., 2008), interfere with mitochondrial function (Parihar and
Brewer, 2010), activate NMDA receptors (Texido et al., 2011), or
activate microglia (Stalder et al., 1999). Importantly, both endoge-
nously and exogenously elevated Aβ may lead to neuronal death
and behavioral dysfunction (Mattson, 2004). Since Aβ peptides
co-accumulate with APP (Smith et al., 1999, 2003b; Uryu et al.,
2007), damaged axons may be a key source of Aβ, released into the
surrounding tissue due to lysis or leakage (Smith et al., 2003c).
Therefore, since neuronal/axonal Aβ peptides, released from
normal neuronal activity and/or from increased production via
injury-induced accumulation of APP, are implicated in the sec-
ondary injury process, Aβ peptides sampled from CSF (Table 3)
or ISF (Table 4) are of interest as biomarkers in TBI.
CSF BIOMARKERS OF Aβ PATHOLOGY FOLLOWING TBI
In the human CSF, Aβ peptides are found throughout life in
their soluble forms. Studies of AD patients have shown that
low CSF Aβ42 concentrations correlate with a high number of
brain plaques (Strozyk et al., 2003). Additionally, some studies
have found increased diagnostic accuracy of the Aβ42/Aβ40 ratio
compared to Aβ42 alone (Hansson et al., 2007).
When the antibodies R165, which specifically recognize Aβ42
and R163, reacting only with Aβ40, were used in combination with
Western Blot and ELISA, CSF Aβ40 and Aβ42 levels were found to
be increased early following severe TBI (Raby et al., 1998; Emmer-
ling et al., 2000) in contrast to normal, (∼50 pg/ml), plasma levels.
On the contrary, decreased CSF Aβ40 and Aβ42 concentrations
have also been observed (Franz et al., 2003; Kay et al., 2003) and
associated with poor clinical outcome (Franz et al., 2003). In lum-
bar CSF, the Aβ40, Aβ42, and total Aβ levels are highly correlated
and may fluctuate markedly over time when serial taps are used
(Bateman et al., 2007). Similar studies in TBI, where CSF samples
are frequently obtained from ventricular CSF, are lacking.
The driving force of Aβ peptides from brain parenchyma into
the interstitial and intraventricular compartments are yet incom-
pletely understood following TBI and may be related to the pres-
ence of cerebral edema and the function of the blood-brain and
brain-CSF barriers (Brightman and Kaya, 2000; Iliff et al., 2012).
The CSF levels of Aβ40 and Aβ42 in controls and AD patients differ
markedly among published studies (Mehta et al., 2000; Frankfort
et al., 2008), similar to the observations in the available TBI studies
(Table 3). Thus, it is plausible that the evaluation method, time
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post-injury and TBI severity, Apoε4 and neprilysin gene status,
the presence of TBI-induced Aβ plaques, and yet undetermined
factors may all influence Aβ levels in CSF. Future studies combin-
ing CSF with ISF levels correlating tissue and behavioral outcome
in addition to the analysis of yet other Aβ peptide species are
needed to determine the clinical value of CSF Aβ peptide levels as
biomarkers.
INTERSTITIAL FLUID BIOMARKERS OF Aβ PATHOLOGY
FOLLOWING TBI
Microdialysis sampling of the ISF has been used for more than
two decades for neurochemical monitoring of the human brain
(Hillered and Persson, 1999; Bellander et al., 2004; Hillered et al.,
2005). MD may be considered mainly a focal sampling method
in contrast to CSF sampling, which reflects more global events
(Hillered et al., 2005). Aβ peptides are regarded normal con-
stituents of human ISF (Seubert et al., 1992), possibly reflecting
a physiological secretion from neuronal metabolism (Hong et al.,
2011). In the pathogenesis of AD, Aβ can aggregate into insolu-
ble species and Aβ oligomeric forms, which have been shown to
be cytotoxic and influence synaptic function (Funke, 2011; Hard,
2011). Although initial Aβ aggregation can occur intracellularly
and/or extracellularly (Meyer-Luehmann et al., 2003; Gouras et al.,
2010), a large amount of the required Aβ peptides comes from a
pool of soluble Aβ in the ISF (Cirrito et al., 2008; Funke, 2011).
To investigate the dynamics of soluble Aβ, hippocampal MD
was used in awake transgenic mice before and during the process
of Aβ plaque formation (Hong et al., 2011). They found that
diffusible forms of Aβ, predominantly Aβ42, came from a large
reservoir of less soluble Aβ42 in brain parenchyma and decreased
in ISF during deposition of Aβ (Hong et al., 2011). Additional
in vitro and in vivo MD experiments were able to demonstrate a
linear correlation between neuronal activity and the interstitial Aβ
concentrations (Kamenetz et al., 2003; Cirrito et al., 2005, 2008).
Following TBI, decreased electroencephalographic (EEG) activ-
ity in the hippocampus occurred concomitantly with decreased
MD hippocampal Aβ levels, supporting the hypothesis that a TBI-
induced reduction in neuronal activity may lead to reduced ISF
Aβ levels (Schwetye et al., 2010).
For human use, most MD studies evaluate either the 20 or the
100 kDA cut-off MD catheters (Hutchinson et al., 2005; Hillman
et al., 2006). Since Aβ40 or Aβ42 peptides have a molecular weight
(MW) of ∼4.5 kDa, both catheters could be used. However, if T-
tau (vide infra) is also evaluated, the 100 kDa catheter needs to be
used due to the 48–67 kDa MW of tau proteins (Ost et al., 2006).
Cerebral MD has recently been used in humans with severe TBI
for the study of interstitial Aβ changes (Brody et al., 2008; Mark-
lund et al., 2009; Magnoni and Brody, 2010; Magnoni et al., 2012)
(Table 4). In an early study, MD and an Aβ1-x ELISA was used to
analyze every Aβ peptide species from amino acid 1–28 or higher
(Brody et al., 2008). A key finding was that ISF Aβ peptides lev-
els were lower than in ventricular CSF explained by a 30% MD
recovery. When Aβ1-x levels were compared to Aβ40 and Aβ42 in
pooled 8 h-samples, the latter were 2.5 and 35 times lower, respec-
tively, suggesting that most Aβpeptides in the injured human brain
are neither Aβ40 nor Aβ42. Finally, in most patients did the ISF Aβ
levels increase over time and the level of consciousness correlated
well with ISF Aβ levels, implying a link to synaptic activity (Brody
et al., 2008). An additional study from the same group (Magnoni
et al., 2012) showed that although the MD Aβ levels were lower
when the MD catheter was placed in the pericontusional tissue
compared to a non-contusional area, pericontusional Aβ levels
increased more substantially over time. Another MD study ana-
lyzed ISF Aβ40 and Aβ42 levels in patients with severe TBI where
higher Aβ42 levels were found in patients with diffuse TBI com-
pared to focal TBI patients (Marklund et al., 2009). Notably, MD
Aβ40 levels were above detection level in only half of the patients
in this study (Marklund et al., 2009).
These studies indicated that MD is a useful tool to study Aβ
dynamics in the injured brain following TBI. Given the lack of
baseline, uninjured control Aβ values, alterations in the Aβ pep-
tides levels following TBI should be interpreted with caution. It has
been hypothesized that reduced Aβ production may be due to neu-
ronal loss and/or decreased synaptic activity (Cirrito et al., 2005,
2008; Brody et al., 2008; Magnoni and Brody, 2010) and may be
increased by axonal injury (Marklund et al., 2009). Although it has
been speculated that toxic Aβ byproducts such as oligomers and
protofibrils initiate cascades ultimately leading to neurodegenera-
tion and dementia (Magnoni and Brody, 2010), available evidence
is insufficient to imply a causative role for the early post-injury Aβ
changes. Moreover, it should be stressed that brain ISF is not in
full equilibrium with the CSF (Fishman, 1992; Brody et al., 2008)
and the half life of Aβ in brain tissue has not been established.
Larger patient series are needed to investigate their relationship
with clinical outcome and discern possible differences between
injured and uninjured brain regions as well as between focal and
diffuse TBI.
TAU AS A BIOMARKER FOLLOWING TBI
Total tau is present in abundance in the central nervous system
and in particular in unmyelinated axons and cortical interneu-
rons (Trojanowski et al., 1989; Sivanandam and Thakur, 2012). Its
biological activity is regulated by phosphorylation (P-tau), which
has been associated with various neuropathologies (Alonso et al.,
2001; Feijoo et al., 2005; Morris et al., 2011). Following human TBI,
C-tau is considered a reliable biomarker of neuronal injury (Shaw
et al., 2002; Zemlan et al., 2002; Gabbita et al., 2005) and has been
suggested to be an indicator of axonal injury (Trojanowski et al.,
1989; Wilhelmsen, 1999; Zemlan et al., 1999; Emmerling et al.,
2000; Franz et al., 2003; Ost et al., 2006; Zetterberg et al., 2006;
Magnoni et al., 2012; Sivanandam and Thakur, 2012). NFTs are
formed by abnormal, phosphorylated tau filaments and CSF tau
are commonly increased 3–4 times in AD (Blennow and Hampel,
2003; Selkoe and Schenk, 2003; Sivanandam and Thakur, 2012).
Tau levels can be markedly increased in the CSF after TBI (Table 3)
and show promise also as a specific serum biomarker in the human
(Liliang et al., 2010b) and experimental setting (Rostami et al.,
2012).
There is evidence to support that P-tau is important in the
development of neurodegeneration (see previous section). Apoε
deficiency and TBI have both been associated with hyperphospho-
rylation of a tau protein domain (Genis et al., 2000; Sivanandam
and Thakur, 2012) (Figure 1). Additionally, tau misprocessing can
be caused by abnormal accumulation of Aβ and tau per se may
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FIGURE 1 | Schematic drawing of interstitial fluid (ISF) and cerebrospinal
fluid (CSF) sampling of tau protein and amyloid-β (Aβ) peptides following
traumatic brain injury (TBI) on a coronal brain section. An external
ventricular drainage (EVD) and a microdialysis (MD) catheter are placed into
the frontal horn of the ventricular system and superficial cortex, respectively.
Initially, TBI results in an accumulation of amyloid precursor protein (APP) that,
following its degradation, may lead to intra-axonal amyloid-β (Aβ) accumulation
and plaque formation in the brain parenchyma. Following TBI, early Aβ plaques
are typically of the diffuse type in contrast to those observed in Alzheimer’s
disease whereas dense plaques may be observed in patients surviving for
many years post-injury. Alternatively, Aβ peptides may also be produced by
normal neuronal activity and be reduced by TBI. Neurofibrillary tangles (NFTs)
can also be formed after TBI as a consequence of hyperphosphorylated tau. In
humans, NFT formation does not appear to occur acutely and has mainly been
observed beyond 4 weeks post-injury following a single, severe TBI. However,
hyperphosphorylated tau aggregations can be observed as a characteristic
observation following repetitive mild TBI. The question marks illustrate the
unknown features of Aβ and tau accumulation, their release into the CSF or
ISF, or the dynamic distribution between the CSF and ISF levels of Aβ
and tau.
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mediate Aβ cytotoxicity in AD (Le et al., 2012), adding to the
complexity of tau and Aβ changes following TBI.
TAU IN CSF AND ISF FOLLOWING TBI
Previous studies have consistently shown that tau CSF levels,
which have been closely linked with the presence of axonal injury,
increased intracranial pressure, and clinical outcome, are increased
in TBI patients compared to normal controls (Zemlan et al., 2002;
Franz et al., 2003; Ost et al., 2006; Zetterberg et al., 2006; Liliang
et al., 2010b; Magnoni et al., 2012) (Table 3). The results are differ-
ent in milder forms of TBI, including boxing, since tau levels are
only slightly increased or even unchanged (Zetterberg et al., 2006;
Neselius et al., 2012). When evaluating tau as a biomarker follow-
ing TBI, it must be considered that ventricular CSF typically has
higher tau levels than lumbar CSF (Blennow and Nellgard, 2004).
Only recently has tau also been analyzed in the ISF (Table 4).
Using MD, ISF T-tau levels were clearly above the detection limit
in all patients and were higher in patients with a focal/mixed TBI
compared to DAI patients (Marklund et al., 2009). The ISF tau
levels were comparable to those previously measured in ventric-
ular CSF post-TBI (Franz et al., 2003; Ost et al., 2006). Recently,
MD tau levels were found to be markedly higher in TBI patients
with the MD probe placed in the pericontusional area compared
to when the MD probe was placed in a brain region without con-
tusions. Additionally, high initial ISF tau levels correlated with
poor clinical outcome (Magnoni et al., 2012). The MD recovery
of tau is likely low, estimated to be 1–2% (Magnoni et al., 2012),
since hyperphosphorylation markedly decreases the solubility of
tau (Table 4). Although T-tau has commonly been analyzed as bio-
markers, the phosphorylation status of tau is likely more important
in the pathophysiology of TBI to date.
CONCLUSION AND FUTURE DIRECTIONS
The current literature on early and late CSF, ISF, and brain tissue
changes of Aβ peptide levels and tau following TBI was reviewed.
To define the precise relation between Aβ and tau levels in brain
tissue, CSF and/or blood and clinical disease remains an important
scientific challenge due to the association between TBI and the risk
of developing neurodegeneration and AD. Available experimen-
tal and clinical evidence implies a complex relationship between
increased tau protein release, Aβ peptide deposition, and NFT and
Aβ plaque formation following TBI. Rodent studies, perhaps most
importantly those carried out in transgenic mice, have provided
important mechanistic information and shed light into many
aspects of tau and Aβ formation following TBI although without
consistently mimicking the histopathological findings observed in
humans. TBI severity, the used species and model, choice of ana-
lytical technique, and the inherent difference between human and
rodent brain may contribute to the inconsistent results obtained
using experimental TBI models. On the other hand, the swine
TBI model appears to produce Aβ pathology more closely resem-
bling the human situation. Only biomarker analysis of Aβ peptides
and tau may not be sufficient to elucidate the complex cellular,
biochemical, genetic (e.g., neprilysin and Apoε4), and metabolic
cascades ultimately predisposing TBI victims to an increased risk
for AD. It appears likely that TBI accelerates the process leading
to AD, although the mechanisms and relation to the acute injury
cascade remain largely unknown. Possibly,many additional in vitro
and in vivo experiments dissecting various aspects of the tau/Aβ
cascade are needed. It is expected that the increased use of tau and
Aβ peptides as biomarkers in the clinical setting will enhance our
understanding of the link between TBI and the later development
of AD.
Available studies show that Aβ and tau can be analyzed in inter-
stitial and CSF although the analysis methods and the resulting
biomarkers levels differ markedly among studies. The studies are
mainly observational and long-term follow up data is frequently
lacking. However, robust data exist for tau, showing elevated lev-
els in the CSF and the ISF and a correlation between tau levels
in both compartments and long-term outcome was also sug-
gested. Emerging data suggest that tau is promising as a biomarker
also in peripheral blood. The interpretation of post-injury Aβ
levels is currently more complicated. Aβ peptides are produced
both by normal neuronal metabolism and by enzymatic process-
ing of accumulated APP in injured axons following TBI. Thus,
their levels may be related to the level of consciousness, the pres-
ence of axonal injury or both and be reduced in the vicinity
of cortical contusions. Importantly, increased Aβ peptide levels,
particularly the longer and fibrillary ones, can also be neuro-
toxic per se (Brody et al., 2008; Marklund et al., 2009; Magnoni
et al., 2012). Different analysis methods also render compar-
isons between studies difficult. Although the Aβ1-42 peptide is
important in AD and has attracted much interest in TBI, other
subspecies may also be highly relevant and much recent interest
is directed toward Aβ oligomers and protofibrils (Magnoni and
Brody, 2010).
Then, what is the current and future potential of tau protein
and Aβ peptides as biomarkers and what can they tell us about
the possible neurodegeneration occurring post-TBI? Ideally, the
levels of a biomarker should closely correlate with a biological or
pathogenic process (Czeiter et al., 2012) or be used as surrogate
end-points. Obviously, the chronic sequelae of TBI survivors are
crucial. However, at the current level of knowledge, the correla-
tion between early Aβ and tau biomarker findings and the later
development of AD is weak. Interestingly, it has been shown that
acute Aβ accumulations can be reversed following TBI (Smith
et al., 1998). Moreover, the vast complexity and variability in the
used TBI models do not allow clear conclusions or extrapolation
of the experimental results into clinical practice to date. Instead,
available evidence suggests that Aβ and tau could be used as injury
markers or in mechanistic studies. In future studies, correlation
of levels in ISF, CSF, and/or serum with advanced neuroimaging
such as diffuse tensor imaging or Positron Emission Tomogra-
phy (PET) using, e.g., Pittsburgh Compound B (Quigley et al.,
2011) preferably using rapid biomarker sampling combined with
enhanced analytical tools could provide additional information.
Long-term and serial biomarker determination would also be
of importance where potential differences in the biomarker lev-
els in lumbar versus ventricular CSF could be evaluated. BACE1
inhibitors, γ-secretase inhibitors, statins, and neprilysin replace-
ment therapy are emerging treatment possibilities for AD which
could also play key roles in the future study of TBI. Combined
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with biomarker analysis, these pharmacological tools could pro-
vide crucial information related to the importance of tau and
Aβ peptides in the pathophysiology and long-term consequences
of TBI.
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